| Pathologic stage |
| Stage 2 vs. 1 |
0.000 |
1.870 |
1.726 |
2.026 |
| Stage 3 vs. 1 |
0.000 |
2.564 |
2.334 |
2.817 |
| White vs. non-white |
0.000 |
1.169 |
1.101 |
1.242 |
| Insurance status |
| Government vs. private |
0.127 |
0.901 |
0.788 |
1.030 |
| Uninsured/unknown vs. private |
0.000 |
1.277 |
1.121 |
1.454 |
| Male vs. female |
0.000 |
0.876 |
0.828 |
0.926 |
| Tumor size (<50 vs. ≥50 mm) |
0.006 |
1.079 |
1.022 |
1.140 |
| Year of diagnosis |
| 2005 vs. 2004 |
0.834 |
1.011 |
0.916 |
1.116 |
| 2006 vs. 2004 |
0.110 |
0.920 |
0.830 |
1.019 |
| 2007 vs. 2004 |
0.484 |
0.964 |
0.868 |
1.069 |
| 2008 vs. 2004 |
0.307 |
1.055 |
0.952 |
1.170 |
| 2009 vs. 2004 |
0.844 |
0.989 |
0.889 |
1.100 |
| 2010 vs. 2004 |
0.020 |
0.880 |
0.790 |
0.980 |
| 2011 vs. 2004 |
0.046 |
0.894 |
0.801 |
0.998 |
| 2012 vs. 2004 |
0.033 |
0.876 |
0.776 |
0.989 |
| Node removed (<20 vs. ≥20) |
0.000 |
0.707 |
0.662 |
0.756 |
| % positive lymph nodes (<10% vs. ≥10%) |
0.000 |
1.426 |
1.318 |
1.543 |
| Chemotherapy (yes vs. no) |
0.000 |
0.684 |
0.634 |
0.738 |
| Radiation (yes vs. no) |
0.000 |
0.862 |
0.801 |
0.926 |
| Residence to treatment facility (<30 vs. ≥30) |
0.002 |
1.106 |
1.038 |
1.179 |
| # of positive lymph nodes (continuous) |
0.000 |
1.036 |
1.027 |
1.044 |
| Facility type (academic vs. non-academic) |
0.005 |
0.925 |
0.877 |
0.976 |
| Charlson/Deyo Comorbidity Score |
| 1 vs. 0 |
0.000 |
1.148 |
1.081 |
1.219 |
| 2+ vs. 0 |
0.000 |
1.543 |
1.411 |
1.688 |
